OA01.04 First-Line Nivolumab + Ipilimumab + Chemotherapy in Metastatic NSCLC: CheckMate 9LA 3-Year Update

D.P. Carbone,L.G. Paz-Ares,T.E. Ciuleanu, M. Cobo-Dols,J. Bennouna,Y. Cheng,H. Mizutani,A. Lingua,F. Reyes,N. Reinmuth,J. Menezes, J. Jassem, S. Protsenko, K. Feeney,E. de la Mora Jimenez,S. Lu,T. John,X. Zhang, N. Hu, M. Reck

Journal of Thoracic Oncology（2023）

引用 0|浏览12

暂无评分

摘要

In CheckMate 9LA (NCT03215706), first-line nivolumab (NIVO) + ipilimumab (IPI) with 2 cycles of chemotherapy (chemo) improved overall survival (OS) versus chemo alone (4 cycles) in patients with metastatic non-small cell lung cancer (mNSCLC). Here, we report updated efficacy and safety results with a 3-year minimum follow-up (previous presentation: Paz-Ares ASCO2022 #LBA9026).

查看译文

关键词

metastatic nsclc,chemotherapy,first-line

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要